COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,100 Articles (22,658 medRxiv, 8,442 bioRxiv)

Most recent first Previous |  Page 1951: Articles 19501-19510  | Next

assayM: a web application to monitor mutations in COVID-19 diagnostic assays.
Mohamed Ghazzali, R. N., Pain, A.
10.1101/2020.12.18.423467 — Posted: 2020-12-18
SNPnexus COVID: Facilitating the analysis of COVID-19 host genetics
Oscanoa, J., Sivapalan, L., Abdollahyan, M., Gadaleta, E., Chelala, C.
10.1101/2020.12.18.423439 — Posted: 2020-12-18
Temporal kinetics of RNAemia and associated systemic cytokines in hospitalized COVID-19 patients
van Riel, D., Embregts, C., Sips, G. J., van den Akker, J., Endeman, H., van Nood, E., van Kampen, J. J., Molenkamp, R., Koopmans, M., van de vijver, d., GeurtsvanKessel, C.
10.1101/2020.12.17.423376 — Posted: 2020-12-18
An infectivity-enhancing site on the SARS-CoV-2 spike protein is targeted by COVID-19 patient antibodies
Liu, Y., Soh, W. T., Tada, A., Arakawa, A., Matsuoka, S., Nakayama, E. E., Li, S., Ono, C., Torii, S., Kishida, K., Jin, H., Nakai, W., Arase, N., Nakagawa, A., Shindo, Y., Kohyama, M., Nakagami, H., Tomii, K., Ohmura, K., Ohshima, S., Okada, M., Matsuura, Y., Standley, D. M., Shioda, T., Arase, H.
10.1101/2020.12.18.423358 — Posted: 2020-12-18 Discussion: Onsite | Offsite
Human Surfactant Protein D Binds S1 and Receptor Binding Domain of Spike protein and acts as an entry inhibitor of SARS-CoV-2 Pseudotyped viral particles in vitro
Hsieh, M.-H., Beirag, N., Murugaiah, V., Chou, Y.-C., Kuo, W.-S., Kao, H.-F., Madan, T., Kishore, U., Wang, J.-Y.
10.1101/2020.12.18.423418 — Posted: 2020-12-18
A new concept on anti-SARS-CoV-2 vaccines: strong CD8+ T-cell immune response in both spleen and lung induced in mice by endogenously engineered extracellular vesicles
Ferrantelli, F., Chiozzini, C., Manfredi, F., Leone, P., Federico, M.
10.1101/2020.12.18.423420 — Posted: 2020-12-18
A recombinant fragment of Human surfactant protein D binds Spike protein and inhibits infectivity and replication of SARS-CoV-2 in clinical samples
Madan, T., Biswas, B., Varghese, P., Subedi, R., Pandit, H., Idicula-Thomas, S., Kundu, I., Rooge, S. B., Aggarwal, R., Tripathi, D., Kaur, S., Gupta, E., Gupta, S., Kishore, U.
10.1101/2020.12.18.423415 — Posted: 2020-12-18
International Comparisons of Harmonized Laboratory Value Trajectories to Predict Severe COVID-19: Leveraging the 4CE Collaborative Across 342 Hospitals and 6 Countries: A Retrospective Cohort Study
Weber, G. M., Hong, C., Palmer, N. P., Avillach, P., Murphy, S. N., Gutierrez-Sacristan, A., Xia, Z., Serret-Larmande, A., Neuraz, A., Omenn, G. S., Visweswaran, S., Klann, J. G., South, A. M., Loh, N. H. W., Cannataro, M., Beaulieu-Jones, B. K., Bellazzi, R., Agapito, G., Alessiani, M., Aronow, B. J., Bell, D. S., Bellasi, A., Benoit, V., Beraghi, M., Boeker, M., Booth, J., Bosari, S., Bourgeois, F. T., Brown, N. W., Chiovato, L., Chiudinelli, L., Dagliati, A., Devkota, B., Follett, R. W., Ganslandt, T., Garcia Barrio, N., Gradinger, T., Griffier, R., Hanauer, D. A., Holmes, J. H., Horki, P., Huling, K. M., Issitt, R. W., Jouhet, V., Keller, M. S., Kraska, D., Liu, M., Luo, Y., Malovini, A., Mandl, K. D., Mao, C., Maram, A., Maulhardt, T., Mauro, B., Milano, M., Moore, J. H., Morris, J. S., Morris, M., Mowery, D. L., Naughton, T. P., Ngiam, K. Y., Norman, J. B., Patel, L. P., Pedrera Jimenez, M., Schriver, E. R., Scudeller, L., Sebire, N. J., Serrano Balazote, P., Spiridou, A., Tan, A. L., Tan, B. W. L., Tibollo, V., Torti, C., Trecarichi, E. M., Trecarichi, M., Vitacca, M., Zambelli, A., Zucco, C., Consortium for Clinical Characterization of COVID-19 by EHR, , Kohane, I. S., Cai, T., Brat, G. A.
10.1101/2020.12.16.20247684 — Posted: 2020-12-18
No evidence of association between schools and SARS-CoV-2 second wave in Italy.
Gandini, S., Rainisio, M., Iannuzzo, M. L., Bellerba, F., Cecconi, F., Scorrano, L.
10.1101/2020.12.16.20248134 — Posted: 2020-12-18 Discussion: Onsite | Offsite
Seroprevalence of anti-SARS-CoV-2 IgG antibodies, risk factors for infection and associated symptoms in Geneva, Switzerland: a population-based study
Richard, A., Wisniak, A., Perez-Saez, J., Garrison-Desany, H., Petrovic, D., Piumatti, G., Baysson, H., Picazio, A., Pennacchio, F., De Ridder, D., Chappuis, F., Vuilleumier, N., Low, N., Hurst, S., Eckerle, I., Flahault, A., Kaiser, L., Azman, A. S., Guessous, I., Stringhini, S., SEROCOV-POP study group
10.1101/2020.12.16.20248180 — Posted: 2020-12-18

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).